Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Positron emission tomography in urological malignancy.

J P Brush1

  • 1Western General Hospital, Edinburgh, UK. jbrush@srv0.med.ed.ac.uk

Current Opinion in Urology
|February 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining Biochemical Cure After Low Dose Rate Prostate Brachytherapy: External Validation of 4-year Prostate-specific Antigen Nadir as a Predictor of 10- and 15-year Disease-free Survival.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

The Importance of Prostate-specific Antigen (PSA) Nadir and Early Identification of PSA Relapse after 10 Years of Prostate Iodine 125 Seed Brachytherapy in Edinburgh.

Clinical oncology (Royal College of Radiologists (Great Britain))·2015
Same author

Multiple lentigines and testicular microlithiasis.

Clinical and experimental dermatology·2001
Same author

Imaging features of leptomeningeal metastases.

Clinical radiology·1999

Positron emission tomography (PET) shows promise for detecting urological tumors and metastases. However, urinary excretion of common radioisotopes limits its effectiveness in pelvic imaging, requiring further research for clinical urology application.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Urology

Background:

  • Positron emission tomography (PET) is a valuable imaging technique for assessing regional metabolism.
  • Clinical applications of PET are established in various cancers and cardiac conditions.
  • PET's role in urological malignancies is under investigation with mixed outcomes.

Purpose of the Study:

  • To review recent advancements in positron emission tomography scanning for urological malignancy.
  • To evaluate the current capabilities and limitations of PET in diagnosing urological cancers.

Main Methods:

  • Review of recent literature on positron emission tomography in urological oncology.
  • Analysis of PET's ability to visualize tumors, lymph nodes, and metastatic sites.
  • Assessment of limitations, particularly radioisotope excretion in the urinary tract.

Related Experiment Videos

Main Results:

  • PET can visualize urological tumors, lymph nodes, and distant metastases.
  • Radioisotope excretion via the urinary tract significantly hinders pelvic imaging effectiveness.
  • PET can detect malignancy in soft tissue masses or lymph nodes earlier than conventional imaging.

Conclusions:

  • PET shows potential for diagnosing urological malignancies and metastases.
  • Current limitations, especially urinary excretion, restrict its widespread clinical use in urology.
  • Larger clinical studies are necessary to establish PET as a standard diagnostic tool in urological oncology.